signal极客公园zh source2026-09-21
不可逆的人类衰老，快被 AI 破解了
In a Phase IIa trial of Insilico Medicine's AI-designed TNIK inhibitor rentosertib for idiopathic pulmonary fibrosis, 42 patients (average age 67) showed biological age reversal across six independently developed aging clocks, with most clocks regressing 3-4 years and one approaching 6 years, based on 326 significantly changed proteins among 2,841 measured. The company, listed on HKEX with a $1.2 billion Sanofi partnership among its deals, uses generative AI for target discovery and molecular design; rentosertib has now advanced to Phase III trials.
- why now
- 2026年9月AI药人体试验首次逆转衰老时钟
- topic
- AI Industry Impact
- source
- 极客公园
score
score 8 out of 10. 0-10: how dense the facts are, multiplied by how much you can do with them after reading. 8+ means the topic's evidence bar is met: benchmarks and availability for a new model, amount and investors for a funding round, revenue figures for a solo-money story. Below 5 an item does not enter the digest. A press release scores 3 or less, a reprint loses 2, anything older than 14 days loses 1, a headline that misleads loses 3.
read the source